CL-BFB759-002 Enrolling

Research Study for Moderate to Severe Atopic Dermatitis (40 Weeks)


Treatment: Injection Age: 18 Years


Who Can Participate?

Adult males and females aged ≥ 18 to ≤ 75 years with atopic dermatitis (AD), may be eligible.

 

Inclusion Criteria:

      • Diagnosis of atopic dermatitis and onset of symptoms for at least 1 year
      • Moderate to severe AD, with a body surface area (BSA) involvement of ≥ 10% (i.e. equal to 10 palm prints on your body)
      • Disease that is not adequately controlled with topical prescription therapies or when those therapies are not advisable
      • Has been using an emollient daily for at least 1 week, and agrees to continue using that same emollient throughout the study

 

Participant Info:

      • No cost to participate or receive study treatment
      • Regular visits with study doctors who are familiar with treating AD
      • Will receive the investigational medication (active study drug) or placebo injected under your skin
      • Reimbursement for study-related expenses may be provided

 

How Long Will The Study Last?

      • Participation will last about 40 weeks and involve about 20 visits to the study research site

Participating Locations

COUNTRY
country-icon
United States
country-icon
Canada

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: August 25, 2025

Official Title

A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Atopic Dermatitis (COMPASS 2-AD)

ClinicalTrials.gov ID

NCT07105488

Sponsor

Bluefin Biomedicine, Inc.

Study Description

  • Brief Summary:

    This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

  • Condition or Disease:

    Atopic Dermatitis (AD)

  • Intervention/Treatment:

    Biological: BFB759 Biological: BFB759,Drug: Placebo Biological: BFB759
  • Phase:

    PHASE 2

  • Ages Eligible for Study:

    18 Years and 75 Years (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

ECZEMA - ATOPIC DERMATITIS

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content